Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
TABLET, FILM COATED
**Dosage and method of administration** **Adults and children aged 12 years and older** The recommended dose is one tablet once daily. **Special risk groups** Studies in special risk groups (elderly, renally or hepatically impaired patients) indicate that it is not necessary to adjust the dose of fexofenadine hydrochloride in these patients.
ORAL
Medical Information
**Indications** **Telfast 180mg** is indicated for the relief of symptoms associated with Seasonal Allergic Rhinitis (SAR) and Chronic Idiopathic Urticaria (CIU) in adults and children 12 years of age and older.
**Contraindications** Fexofenadine is contraindicated in patients with known hypersensitivity to any of its ingredients.
R06AX26
fexofenadine
Manufacturer Information
OPELLA HEALTHCARE SINGAPORE PTE. LTD.
PT. Aventis Pharma
Active Ingredients
Documents
Package Inserts
Telfast Tablet 180mg PI.pdf
Approved: August 12, 2020